Clinical trials: Genital Neoplasm
No Condition
Comparison of Clinical Outcomes Between IVM and Minimal Stimulation IVF in Patients With PCOS
Polycystic ovarian syndrome (PCOS) is most common endocrinologic disease in women of reproductive age with incidence of 6.6 ~ 8%.
- Trial name
- NCT03134482
- Testing
- IVM, Minimal stimulation IVF
- Where
- 2 sites in South Korea
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- CHA University
Prostate Cancer
Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with metastatic…
- Trial name
- NCT00003626
- Testing
- dolastatin 10
- Where
- 3 sites in United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Ovarian Cancer
Evaluation of Safety, Tolerability, Pharmacokinetics, Food Effect and Interaction With Midazolam in Healthy Volunteers After Oral Single and Multiple Ascending Dosing of KAND145
The goal of this study is to learn more about the study candidate drug, KAND145, when given to healthy volunteers. The study will consist of two parts.
- Trial name
- NCT06063343
- Testing
- KAND145
- Where
- Finland
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Novakand Pharma AB
Prostate Cancer
Atrasentan in Treating Patients With Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase III trial to determine the effectiveness of atrasentan in treating patients who have prostate…
- Trial name
- NCT00046943
- Testing
- atrasentan hydrochloride
- Where
- United States
- Sponsor
- Abbott
Ovarian Cancer
Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer
The purpose of this study is to evaluate the safety and activity of adding pazopanib to weekly chemotherapy with paclitaxel for patients with ovarian cancer that is resistant or refractory to treatment with platinum based therapy.
- Trial name
- MITO-11 (NCT01644825)
- Testing
- paclitaxel, pazopanib
- Where
- 20 sites in Italy
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute, Naples
Ovarian Cancer
The Epigenetic Regulatory Role of P-element Induced Wimpy Testis (Piwi) Interacting RNA-823 (piR-823) in Ovarian Cancer Progression
Ovarian cancer (OC) has one of the highest mortality rates for female malignant tumors, attributed to advanced cancer stages upon diagnosis as well as a high recurrence rate.
- Trial name
- NCT06320418
- Where
- Egypt
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Metastatic Prostate Cancer
The Role of Ga68-PSMA-11 PET Imaging in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
This is an open-label single arm clinical trial, Plan to enroll approximately a total of 43 evaluable subjects. According to the estimated missing rate 15%, the sample size in this study is 51.
- Trial name
- NCT03977610
- Testing
- Ga-68 PSMA ligand
- Where
- Taiwan
- Volunteers
- 46 people
- Sponsor
- Chang Gung Memorial Hospital
Ovarian Cancer, Neoplasm, Ovarian
Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer
In this study, The researchers sought to explore the efficacy and safety of involving field radiotherapy in the oligo-metastatic/recurrent/refractory ovarian cancer patients among different groups which include drug therapy…
- Conditions
- Ovarian Cancer, Neoplasm, Ovarian, Ovarian Neoplasm, Ovary Neoplasms
- Trial name
- NCT05059782
- Testing
- chemotherapy, targeted therapeutics, immunotherapy, IFRT, IMRT or SBRT
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Xi'an Jiaotong University
Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other…
- Conditions
- Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Neuroendocrine Carcinoma
- Trial name
- NCT03866382
- Testing
- Biospecimen Collection, Bone Scan, Cabozantinib S-malate
- Where
- 582 sites in United States, Puerto Rico
- Volunteers
- 314 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as sirolimus, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00311623
- Testing
- Rapamycin 3mg, Rapamycin 6mg, Radical prostatectomy
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cervical Dysplasia
Can Alternative Treatment Have an Impact on Cervical Dysplasia?
In this study two questions will be answered: can mindfulness meditation help cell-changed on the cervix to disappear? can mindfulness meditation lower the psychological distress when women have abnormal cervical cancer screening…
- Trial name
- NCT00842738
- Testing
- Mindfulness meditation, No meditation, Controls
- Where
- Denmark
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Tobacco, Tobacco Abstinence
Quitting Matters Human Immunodeficiency Virus Hybrid Trial
The purpose of this study is to compare the advantages and disadvantages of two approaches for quitting smoking among people living with HIV (PWH).
- Conditions
- Tobacco, Tobacco Abstinence, Smoking Cessation, Smoking Cessation; Tobacco Dependence
- Trial name
- QMH (NCT06883097)
- Testing
- Learn to Quit-HIV (LTQ-H) App, QuitStart
- Where
- United States
- Volunteers
- 314 people
- Sponsor
- Wake Forest University Health Sciences
Human Papillomavirus Type 16, Cervical Intraepithelial Neoplasia Grade II
HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia
The primary goal of this phase I open label study is to determine the safety and tolerability of pNGVL4aCRTE6E7L2 DNA vaccine, as administered by intramuscular (IM) injection with TriGrid™ electroporation to both HIV- or HIV+…
- Conditions
- Human Papillomavirus Type 16, Cervical Intraepithelial Neoplasia Grade II, Cervical Intraepithelial Neoplasia, Grade III
- Trial name
- NCT04131413
- Testing
- pNGVL4aCRTE6E7L2
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer, Ovarian Cancer
Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence
The goal of this clinical trial is to test whether psilocybin along with therapy in women with early breast cancer and ovarian cancer in remission can improve their fear of recurrence.
- Trial name
- NCT06430541
- Testing
- Psilocybin
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Colorado, Denver
Depression, Cancer
Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET)
The purpose of this study is to develop and test a new intervention to reduce depressive symptoms in post-treatment cancer participants.
- Conditions
- Depression, Cancer, Stage III Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT06811454
- Testing
- MINDSET, Enhanced Usual Care (EUC)
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Case Comprehensive Cancer Center
Ovarian Cancer, Non-small Cell Lung Cancer
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
The goal of this clinical study is to learn more about the study drug, TUB-040, including its safety, tolerability, pharmacokinetics, and preliminary efficacy, and to determine the best dose of TUB-040 in participants with…
- Trial name
- NAPISTAR1-01 (NCT06303505)
- Testing
- TUB-040, Bevacizumab
- Where
- 21 sites in United States, Belgium and 5 more
- Volunteers
- 334 people
- Sponsor
- Gilead Sciences
Advanced Solid Malignancies
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that…
- Trial name
- CERTIS1 (NCT05417594)
- Testing
- AZD9574, Temozolomide (TMZ), [11C]AZ1419 3391
- Where
- 32 sites in United States, Australia and 5 more
- Volunteers
- 695 people
- Sponsor
- AstraZeneca
Prostatic Neoplasms
A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)
The purpose of this study is to assess the safety and pharmacokinetics of niraparib when administered in combination with an androgen receptor (AR)-targeted therapy (apalutamide or abiraterone acetate plus prednisone) in adult…
- Trial name
- NCT02924766
- Testing
- Niraparib, Apalutamide, Abiraterone Acetate
- Where
- 6 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
Assessing the Potential for Reduced Toxicity Using Focal Brachytherapy in Early Stage, Low Volume Prostate Cancer
The purpose of this study is to see what side effects a type of radiation treatment called focal brachytherapy has in treating early stage prostate cancer.
- Trial name
- NCT01354951
- Testing
- Prostate Biopsy, Focal Brachytherapy , Assessment of QOL
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Targeted Therapy, Chemotherapy
Donafenib for Recurrent Cervical Cancer
This study is to evaluate the safety and tolerability of Donafenib combined with paclitaxel and platinum ± programmed death 1 monoclonal antibody (PD-1 antibody) in patients with recurrent cervical cancer.
- Conditions
- Targeted Therapy, Chemotherapy, Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma
- Trial name
- NCT05310331
- Testing
- Donafenib combined with paclitaxel and platinum ± PD-1 antibody
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Lei Li
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.